Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187864 | 0.82 | MAPT (0.43) | KDM4EMAP4K4MAPTMAPK1L3MBTL1 | |
| SCHEMBL17185819 | 0.81 | PLK1 (0.50) | ALDH1A1MAPK1LMNA | |
| SCHEMBL2039580 | 0.81 | MAP4K4 (0.69) | HSD17B10MAP4K4CA1CA2 | |
| SCHEMBL4038270 | 0.80 | MAPK1 (0.55) | KDM4EALDH1A1CA1CA2MAPT | |
| SCHEMBL2715514 | 0.80 | NNMT (0.58) | MAP4K4CA1CA2MAPK1NNMT | |
| SCHEMBL186124 | 0.78 | MAPT (0.59) | KDM4EALDH1A1ALOX15HSD17B10P4HA1 | |
| SCHEMBL15514113 | 0.78 | HCAR3 (0.50) | KDM4EALDH1A1ALOX15HSD17B10P4HA1 | |
| SCHEMBL27717025 | 0.77 | BAZ2B (0.42) | KDM4EMAP4K4MAPTL3MBTL1NNMT | |
| SCHEMBL840770 | 0.77 | KMT2A (0.50) | KDM4EALDH1A1ALOX15HSD17B10P4HA1 | |
| SCHEMBL20588333 | 0.77 | HPGDS (0.53) | KDM4EALDH1A1ALOX15HSD17B10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| CN-103814021-B | Dihydroquinoline 2 ketone derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-21 | — | — | CN | claimed |
| CN-103249727-B | Biaryl amide derivatives | 霍夫曼-拉罗奇有限公司 | 2016-08-10 | — | — | CN | claimed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | claimed |
| CN-103328436-B | Aryl-Benzocycloalkylamide Derivatives | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | claimed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | claimed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | claimed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | claimed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | claimed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | claimed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | claimed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | KDM4E 2244/4885ALDH1A1 974/4885ALOX15 4786/4885 |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | KDM4E 3381/4885ALDH1A1 923/4885ALOX15 1685/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | KDM4E 2244/4885ALDH1A1 974/4885ALOX15 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.